Topic: chronic kidney disease
Johnson & Johnson unveiled new data showing how its Invokana can benefit patients with Type 2 diabetes and chronic kidney disease.
AstraZeneca's latest diabetes awareness rollout features a fisherman who likens his stalling boat engine to a bad heart.
With China's large and increasing chronic kidney disease population, roxadustat could hit $1 billion in that country alone by 2025.
J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.
In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.
Novartis' canakinumab, a rare disease med it's studying for the heart, cut CV risks in patients with diabetes and chronic kidney disease, data shows.
Keryx’s Auryxia has struggled. But with its latest FDA nod, the company’s prepping for a launch that it thinks can boost the drug.
Lilly and BI believe their SGLT2 inhibitor, Jardiance, may improve outcomes for chronic kidney disease patients—so they’re putting the med to the test.